[Autism and ADHD across the life span. Differential diagnoses or comorbidity?]
- PMID: 21484168
- DOI: 10.1007/s00115-010-3239-6
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?]
Abstract
Exclusion criteria of the DSM-IV-TR and ICD-10 do prevent dual diagnoses of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). However, inattention, impulsivity and hyperactivity are amongst the most frequent associated symptoms of ASD. Psychopathological, neuropsychological, brain imaging and genetic studies suggest possible pathophysiological links between ASD and ADHD. Thus, standard diagnostic procedures for both disorders should assess the presence of potential comorbid symptoms of the other disorder. Treatment strategies for ADHD symptoms in the context of ASD overlap with those for patients with ADHD, but lower dosages and slower titration might be recommendable.
Similar articles
-
[Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].Neuropsychiatr. 2007;21(3):187-206. Neuropsychiatr. 2007. PMID: 17915180 Review. German.
-
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25. J Am Acad Child Adolesc Psychiatry. 2012. PMID: 22721596 Clinical Trial.
-
Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.J Child Adolesc Psychopharmacol. 2006 Oct;16(5):611-9. doi: 10.1089/cap.2006.16.611. J Child Adolesc Psychopharmacol. 2006. PMID: 17069549
-
Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.J Child Adolesc Psychopharmacol. 2013 Apr;23(3):194-9. doi: 10.1089/cap.2012.0012. Epub 2013 Apr 11. J Child Adolesc Psychopharmacol. 2013. PMID: 23578015 Clinical Trial.
-
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].Rev Neurol. 2013 Sep 6;57 Suppl 1:S205-10. Rev Neurol. 2013. PMID: 23897149 Review. Spanish.
Cited by
-
Peripheral Inflammatory Markers Contributing to Comorbidities in Autism.Behav Sci (Basel). 2016 Dec 14;6(4):29. doi: 10.3390/bs6040029. Behav Sci (Basel). 2016. PMID: 27983615 Free PMC article.
-
Correlation between Autism Treatment Evaluation Checklist (ATEC) and Childhood Autism Rating Scale (CARS) in the evaluation of autism spectrum disorder.Sudan J Paediatr. 2016;16(1):17-22. Sudan J Paediatr. 2016. PMID: 27651549 Free PMC article.
-
Comprehensive Description of Comorbidity for Autism Spectrum Disorder in a General Population.Perm J. 2017;21:16-088. doi: 10.7812/TPP/16-088. Perm J. 2017. PMID: 28241914 Free PMC article.
-
Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond.J Neural Transm (Vienna). 2020 Feb;127(2):251-263. doi: 10.1007/s00702-020-02155-5. Epub 2020 Feb 18. J Neural Transm (Vienna). 2020. PMID: 32072336 Free PMC article.
-
Characterization of Clinical Manifestations in the Co-occurring Phenotype of Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.Front Psychol. 2020 May 15;11:861. doi: 10.3389/fpsyg.2020.00861. eCollection 2020. Front Psychol. 2020. PMID: 32499739 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical